Davabazaar in India Vision and Objective

Davabazaar in India website is a Pharma Trade Portal which caters to end patients and their relatives, chemist and medical stores, pharmacist and other pharma workers, doctors and nursing homes, hospitals and medical institutions, pharmaceutical manufactures and allied service providers, trade and manufactures associations.

For patients and relatives we have Ask-the-Doctor medical forums, health blogs, chats and patient health communities. Read more »

Drug Index Software

Very soon the drug index software will be available for download. This software and all further upgrades are available free of cost to chemist and medical doctors. Please register and get yourself verified. Pharmaceutical companies who wish to add their information should also register and get verified.

Correspondent's picture

Pharma Overview

Wed, 08/12/2009 - 00:24 — Correspondent

Pharmaceutical OverviewLast Updated: April 2009

Sector structure/Market size


The Indian pharmaceutical industry is driving product development and breaking new grounds in medicine research worldwide.


The Indian domestic pharmaceutical market is estimated to be US$ 10.76 billion in 2008 and is expected to grow at a high compound annual growth rate (CAGR) of 9.9 per cent till 2010 and thereafter at a CAGR of 9.5 per cent till 2015. Read more »

Correspondent's picture

Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness

Tue, 02/09/2010 - 04:31 — Correspondent

Pfizer and Keas announced today they have entered into an alliance to collaborate on the Keas platform to enable Health and Wellness experts to author, sell and distribute personalized online Care Plans directly to patients.

Correspondent's picture

analytica InnovationArea: Start-ups in the Spotlight

Tue, 02/09/2010 - 04:30 — Correspondent

23-26 March 2010, Munich, Germany.
Following its successful premiere in 2008, analytica, the leading trade fair for industrial analysis, laboratory technology and biotechnology, will continue its initiative for new companies again in 2010.

Correspondent's picture

TGA Seeks to Update Child-Resistant Packaging Requirements

Tue, 02/09/2010 - 02:30 — Correspondent

Australia’s Therapeutic Goods Administration (TGA) is proposing to add angiotensin II antagonists to the classes of medicines requiring child-resistant packaging (CRP).

Correspondent's picture

Repros Submits Revised Male Fertility Indication for Androxal

Tue, 02/09/2010 - 02:30 — Correspondent

At the FDA’s request, Repros Therapeutics has submitted a revised indication to investigate Androxal oral tablets as a low-testosterone treatment for hypogonadal men.

Correspondent's picture

IntelGenx’s Generic Wellbutrin XL Delayed by Complete Response Letter

Tue, 02/09/2010 - 02:30 — Correspondent

The FDA’s complete response letter for IntelGenx’s generic version of Wellbutrin XL delays introduction of the product at least until late 2010.

Correspondent's picture

Industry Cites Excess Burden, Lack of Guidance in Proposed Combo GMP Rule

Tue, 02/09/2010 - 02:30 — Correspondent

Combination-product stakeholders suggest that the FDA’s proposed rule on good manufacturing practices (GMPs) for those products add postapproval change control guidance, simplify other requirements and extend the waiting period for the rule to take effect.

Correspondent's picture

Anthera, FDA Confirm SPA on Phase III Trial for Varespladib

Tue, 02/09/2010 - 02:30 — Correspondent

Anthera Pharmaceuticals and the FDA have agreed on a special protocol assessment (SPA) for a Phase III trial of the company’s acute coronary syndrome candidate varespladib.

Syndicate content